Effect of accurate heart delineation on cardiac dose during the CONVERT Trial.
dc.contributor.author | Groom, N | |
dc.contributor.author | Wilson, E | |
dc.contributor.author | Faivre-Finn, Corinne | |
dc.date.accessioned | 2017-04-18T08:01:48Z | |
dc.date.available | 2017-04-18T08:01:48Z | |
dc.date.issued | 2017-03-31 | |
dc.identifier.citation | Effect of accurate heart delineation on cardiac dose during the CONVERT Trial. 2017, Br J Radiol | en |
dc.identifier.issn | 1748-880X | |
dc.identifier.pmid | 28362511 | |
dc.identifier.doi | 10.1259/bjr.20170036 | |
dc.identifier.uri | http://hdl.handle.net/10541/620240 | |
dc.description.abstract | This study investigates the effect of deviation from protocol in heart delineation for the CONVERT Trial ( ClinicalTrials.gov Identifier NCT00433563) quality assurance (QA) programme, and the effect of that on mean cardiac dose and percentage of heart volume receiving ≥5Gy (V5%) and ≥30Gy (V30%). | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to The British journal of radiology | en |
dc.title | Effect of accurate heart delineation on cardiac dose during the CONVERT Trial. | en |
dc.type | Article | en |
dc.contributor.department | Mount Vernon Cancer Centre, Northwood, UK | en |
dc.identifier.journal | The British Journal of Radiology | en |
html.description.abstract | This study investigates the effect of deviation from protocol in heart delineation for the CONVERT Trial ( ClinicalTrials.gov Identifier NCT00433563) quality assurance (QA) programme, and the effect of that on mean cardiac dose and percentage of heart volume receiving ≥5Gy (V5%) and ≥30Gy (V30%). |